ERYTech: Dense newsflow to come in H2

CORPORATE, Fair Value EUR16.5 (+70%)

News published on August Thursday 29, 2013
Share on

Erytech released unsurprising financials results for H1 with a solid cash position of EUR18.5m. The company is also giving updates on key clinical developments for Graspa: 1/ enrolment of the pivotal phase III in Acute Lymphoblastic Leukaemia is near completion and results are confirmed to be available in Q3 2014; and 2/ more than 20% of patients have been recruited in Acute Myeloid Leukaemia (AML) at a faster pace than expected. With the completion of the enrolment in the ALL Phase III, we expect the first patient treated in the US Phase I as well as the start of a clinical trial in solid tumours. Therefore, we expect several important announcements in H2.

Full report available to subscribers
Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities